Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

Abstract Background We performed a pooled analysis of the COMPARZ study assessing efficacy and safety of pazopanib versus sunitinib in treatment-naïve Chinese patients with locally advanced and/or metastatic renal cell carcinoma (a/mRCC). Methods In the COMPARZ study, patients were randomized (1:1)...

Full description

Bibliographic Details
Main Authors: Xinan Sheng, Jie Jin, Zhisong He, Yiran Huang, Aiping Zhou, Jinwan Wang, Xiubao Ren, Dingwei Ye, Xu Zhang, Shukui Qin, Fangjian Zhou, Binhui Wang, Jun Guo
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
Renal cell carcinoma
Pazopanib
Sunitinib
Chinese
Online Access:http://link.springer.com/article/10.1186/s12885-020-6708-8

Internet

http://link.springer.com/article/10.1186/s12885-020-6708-8

Similar Items